Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral nicorandil for prevention of contrast-induced nephropathy after PCI in coronary artery disease with renal insufficiency
ChiCTR-IPR-17012805Phase 4Not yet recruiting
- Sponsor
- Southeast University
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of nicorandil in contrast-induced nephropathy (CIN) (2 arms), sponsored by Southeast University. Primary endpoint: Incidence of contrast-induced nephropathy. Planned start Nov 2017; status: not yet recruiting.
02
Drugs
nicorandil
03
Conditions
contrast-induced nephropathy (CIN)
Beyond the preview
Go deeper on ChiCTR-IPR-17012805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17012805.